6 Meridian’s Coherus Oncology CHRS Stock Holding History

6 Meridian’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,882	Closed	-$150K	–	412
2021 Q2	$150K	Buy	10,882 +446	+4%	+$6.32K	0.01%	387
2021 Q1	$152K	Buy	+10,436	New	+$177K	0.01%	396

Other funds holding CHRS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

6 Meridian's CHRS Position: Q3 2021 in Review

6 Meridian sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 10,882 shares — an estimated $150K sold.

6 Meridian first reported a position in CHRS in Q1 2021 and held it in 2 quarters. The position peaked at $152K in Q1 2021. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

6 Meridian reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 10,882 Coherus Oncology shares in Q3 2021, an estimated $150K.
6 Meridian first reported a position in Coherus Oncology in Q1 2021 and held it in 2 quarters.
6 Meridian's Coherus Oncology position peaked at $152K in Q1 2021.
187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.